✦ LIBER ✦

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

✍ Scribed by Hill, Simon; Elhilali, Mostafa; Millard, Richard J; Dwyer, Peter L; Lheritier, Karine; Kawakami, Fernando T.; Steel, Michael

Book ID: 121222527
Publisher: Informa plc
Year: 2007
Tongue: English
Weight: 329 KB
Volume: 23
Category: Article
ISSN: 0300-7995
DOI: 10.1185/030079907X233160

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term treatment with darifenacin for

Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study

✍ François Haab; Jacques Corcos; Paul Siami; Karin Glavind; Peter Dwyer; Michael S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

LONG-TERM TREATMENT OF OVERACTIVE BLADDE

LONG-TERM TREATMENT OF OVERACTIVE BLADDER WITH DARIFENACIN IN OLDER PATIENTS: ANALYSIS OF RESPONDER RATES IN A 2-YEAR, OPEN-LABEL EXTENSION STUDY

✍ F. Haab; S. Hill; K. Lheritier; F.T. Kawakami; M. Gittelman 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 62 KB

PUK28 LONG-TERM DARIFENACIN TREATMENT FO

PUK28 LONG-TERM DARIFENACIN TREATMENT FOR OVERACTIVE BLADDER: QUALITY OF LIFE OUTCOMES FROM A 2-YEAR, OPEN-LABEL EXTENSION STUDY

✍ J Young; K Lheritier; M Steel; P Dwyer 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Long-term benefits of darifenacin treatm

Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study

✍ Peter Dwyer; Con Kelleher; Jay Young; François Haab; Karine Lheritier; Rinat Ari 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 1 views

LONG-TERM EFFICACY AND SAFETY PROFILE OF

LONG-TERM EFFICACY AND SAFETY PROFILE OF EZETIMIBE10MG IN TREATMENT OF PATIENTS WITH HOMOZYGOUS SITOSTEROLEMIA: A MULTI-CENTER, OPEN-LABEL, 2-YEAR EXTENSION STUDY

✍ Luetjohann, D.; von Bergmann, K.; Sirah, W.; Shah, A.; Lin, J.; Sapre, A.; Johns 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Long-term efficacy and safety of adalimu

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

✍ Kenneth Gordon; Kim Papp; Yves Poulin; Yihua Gu; Stephen Rozzo; Eric H. Sasso 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 347 KB